Meeting Banner
Abstract #3358

Efficacy of Gadoterate Meglumine enhanced MRA in evaluating thoracic aortic aneurysm and comparison with Gadobutrol enhanced MRA

Kaitlin Crawford1, Ali Serhal2, Olivia D. Reese2, Pascale Aouad2, Matthew Barrett2, Monica Korell2, Amir Rahsepar2, Monda Shehata2, Ahmadreza Ghasemiesfe2, Jeremy Collins2, and James Carr2,3

1University of Notre Dame, South Bend, IN, United States, 2Northwestern University, Chicago, IL, United States, 3Knight Family Professor of Cardiac Imaging, Chicago, IL, United States

Contrast enhanced Magnetic resonance imaging plays an important role in the diagnosis and follow-up of patients with thoracic aortic aneurysm (TAA). Gadoterate Meglumine, which has recently become available in the US, is considered one of the safer gadolinium contrast agents with respect to tissue deposition and NSF, due its macrocyclic structure. In this study, we compare the qualitative image quality and quantitative aortic dimensions of Gadoterate Meglumine enhanced MRA and compare it to Gadobutrol enhanced MRA for evaluation of thoracic aortic disease. These preliminary results showed that Gadoterate Meglumine enhanced MRA has comparable image quality to Gadobutrol enhanced MRA and excellent correlation with respect to aortic diameter measurements.

This abstract and the presentation materials are available to members only; a login is required.

Join Here